Abeona Therapeutics Inc. announced that the last patient has completed their 6-month follow-up visit in Abeona's pivotal Phase 3 VIITAL study of its investigational autologous, engineered cell therapy, EB-101, in patients with recessive dystrophic epidermolysis bullosa. Abeona has been verifying and preparing the data in real time to ensure that an efficient database lock can be completed within two to three weeks from the last patient's final visit. Abeona expects the VIITAL study, if positive, to serve as the basis for seeking approval by the U.S. Food and Drug Administration (FDA) of EB-101 for the treatment of patients with RDEB.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.44 USD | +5.52% | -53.26% | -31.34% |
04-23 | Sector Update: Health Care Stocks Rise Late Afternoon | MT |
04-23 | Top Midday Decliners | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.34% | 89.18M | |
+1.77% | 42.75B | |
+47.70% | 41.61B | |
+12.24% | 41.34B | |
-8.83% | 26.59B | |
+7.44% | 25.49B | |
-23.01% | 18.12B | |
+30.56% | 12.24B | |
-1.82% | 11.76B | |
+8.35% | 11B |
- Stock Market
- Equities
- ABEO Stock
- News Abeona Therapeutics Inc.
- Abeona Therapeutics Inc. Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa